The experience of managing patients with anxiety disorders in real clinical practice

Anxiety disorders (AD) are one of the main health care challenges. Epidemiological studies indicate that ADs occur in 21–30% of the population over a lifetime. The annual prevalence of AD in the USA is 18.1%, with a lifetime prevalence of 28.2%. In Europe, the annual prevalence ranges from 12 to 27%, with a lifetime prevalence of about 21–30%. In Russia, the frequency of AD varies from 16 to 31%, more commonly found in women and starting at a young age. Treating AD is complex due to the potential negative impact of medications on psychophysiological functions. It is important to select therapy considering its effectiveness, safety, and availability, especially after the COVID-19 pandemic. Treatment of AD includes psychotherapy and psychopharmacotherapy. Normally, neurons that limit and implement anxiety are in equilibrium. During anxiety, the activity of neurons limiting anxiety decreases, while the activity of neurons implementing anxiety increases. The goal of therapy is to activate GABAergic and serotonergic neurons to reduce anxiety. In recent years, a comprehensive therapy consisting of two types of drugs has been used in the treatment of AD: SSRIs and a serotonin tranquilizer called buspirone. Buspirone is a non-benzodiazepine anxiolytic effective in treating AD. It has fewer side effects compared to benzodiazepines. Buspirone acts on serotonin receptors of the 1A-type, providing a gradual reduction of anxiety. It can also be used for monotherapy of GAD, augmentation of antidepressant therapy, and is actively applied in routine neurological practice. It has significant therapeutic potential, a sufficiently small profile of side effects, and good tolerability. The article is illustrated by a clinical case of the successful use of buspirone.

1. Shevlin M, McBride O, Murphy J, Miller JG, Hartman TK, Levita L et al. Anxiety, depression, traumatic stress and COVID-19-related anxiety in the UK general population during the COVID-19 pandemic. BJPsych Open. 2020;6(6):e125. https://doi.org/10.1192/bjo.2020.109.

2. Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A et al. The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective. J Clin Psychiatry. 2022;83(3):21m14116. https://doi.org/10.4088/jcp.21m14116.

3. Nikiforov IA, Aronov PV, Belskaya GN. Clinical experience in patient management with anxiety disorder. RMJ. 2023;(3):35–38. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Klinicheskiy_opyt_vedeniya_pacientov_s_trevoghnym_rasstroystvom/.

4. Korabelnikova EA. Anxiety disorders in the context of the Covid-19 pandemic. Medical News of North Caucasus. 2021;16(1):79–85. (In Russ.) https://doi.org/10.14300/mnnc.2021.16022.

5. Tee ML, Tee CA, Anlacan JP, Aligam KJG, Reyes PWC, Kuruchittham V, Ho RC. Psychological impact of COVID-19 pandemic in the Philippines. J Affect Disord. 2020;277:379–391. https://doi.org/10.1016/j.jad.2020.08.043.

6. Khan AH, Sultana MS, Hossain S, Hasan MT, Ahmed HU, Sikder MT. The impact of COVID-19 pandemic on mental health & wellbeing among home-quarantined Bangladeshi students: A cross-sectional pilot study. J Affect Disord. 2020;277:121–128. https://doi.org/10.1016/j.jad.2020.07.135.

7. Pisova NV, Pisov AV. Depression and Post-traumatic Stress Disorder in Patients with COVID-19. Lechebnoe Delo. 2020;(1):82–88. (In Russ.) Available at: https://elibrary.ru/shrmud.

8. Bäuerle A, Teufel M, Musche V, Weismüller B, Kohler H, Hetkamp M et al. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. J Public Health. 2020;42(4):672–678. https://doi.org/10.1093/pubmed/fdaa106.

9. Dmitriev MN, Baeva DO, Slavgorodskaya MS. A clinical case of the new-onset bipolar affective disorder in the postcovid period. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2024;124(3):125–129. (In Russ.) https://doi.org/10.17116/jnevro2024124031125.

10. Levin OS, Chimagomedova ASh, Arefyeva AP. Anxiety in the elderly. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(6):113–118. (In Russ.) https://doi.org/10.17116/jnevro2019119061113.

11. Bobrov AE, Usatenko EV. The concept of anxiety disorders: main development trends. Social and Clinical Psychiatry. 2021;31(4):62–70. (In Russ.) Available at: https://www.elibrary.ru/qammeh.

12. Martynikhin IA. Gender differences in the epidemiology and pathogenesis of depressive and anxiety disorders in the context effectiveness of sertraline (Zoloft). Psikhiatriya i Psikhofarmakoterapiya. 2019;(3):52–58. (In Russ.) Available at: https://www.elibrary.ru/xboaqx.

13. Dzampaev AT, Suvorova IA, Damulin IV. Clinical potential and possibilities of using buspirone in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(8):94–104. (In Russ.) Available at: https://www.elibrary.ru/stxutz.

14. Chizhova OA, Yuzbashyan PG. Alexithymia and self-harm in people with borderline personality disorder. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2024;124(1):102–108. (In Russ.) https://doi.org/10.17116/jnevro2024124011102.

15. Leichsenring F, Heim N, Leweke F, Spitzer C, Steinert C, Kernberg OF. Borderline Personality Disorder: A Review. JAMA. 2023;329(8):670–679. https://doi.org/10.1001/jama.2023.0589.

16. Asmundson GJG, Taylor S. Coronaphobia: Fear and the 2019-nCoV outbreak. J Anxiety Disord. 2020;70:102196. https://doi.org/10.1016/j.janxdis.2020.102196.

17. Dutheil F, Mondillon L, Navel V. PTSD as the second tsunami of the SARS-Cov-2 pandemic. Psychol Med. 2021;51(10):1773–1774. https://doi.org/10.1017/s0033291720001336.

18. Romasenko LV, Alexandrovsky YuA, Makhov VM, Chichkova NV, Parkhomenko IM, Kadushina EB et al. Generalized anxiety disorder in patients of general medical practice: clinical features, therapy. Psikhiatriya i Psikhofarmakoterapiya. 2015;(3):56–59. (In Russ.) Available at: https://www.elibrary.ru/ukkehn.

19. Shavlovskaya OA, Kuznetsov SL. Correction of anxiety disorders: focus on a comorbid patient. Terapevticheskii Arkhiv. 2018;90(4):67–71. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/32479.

20. Medvedev VE. Anxiety and depression in COVID-19: treatment options. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):111–116. (In Russ.) https://doi.org/10.14412/2074-2711-2021-2-111-116.

21. An anxious age, anxious hearts. XV interdisciplinary conference “Vane readings”. Egis Satellite Symposiumon. Effective Pharmacotherapy. 2019;15(14):50–56. (In Russ.) Available at: https://umedp.ru/upload/iblock/3c1/effektivnaya_farmakoterapiya_nevrologiya_i_psikhiatriya_2_2019.pdf.

22. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768–777. https://doi.org/10.1016/s0140-6736(18)31793-8.

23. de Vries YA, de Jonge P, van den Heuvel E, Turner EH, Roest AM. Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. Br J Psychiatry. 2016;208(6):515–521. https://doi.org/10.1192/bjp.bp.115.173450.

24. Roles S. The largest meta-analysis of pharmaceutical treatments of Generalised Anxiety Disorder consolidates current knowledge and reveals convincing effectiveness of Venlafaxine. Evid Based Nurs. 2020;23(3):74. https://doi.org/10.1136/ebnurs-2019-103111.

25. Duan L, Zhu G. Psychological interventions for people affected by the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):300–302. https://doi.org/10.1016/s2215-0366(20)30073-0.

26. Troitsky MS, Tokarev AR, Panshina MV. Possibilities of non-medicine and medicinal therapies of alert disorders (literature review). Journal of New Medical Technologies. 2018;25(1):61–70. (In Russ.) https://doi.org/10.24411/1609-2163-2018-15995.

27. Ladyzhensky MYa, Gorodnichev AV, Kostyukova EG. Benzodiazepine anxiolytics: demand are they today? Current Therapy of Mental Disorders. 2014;(2):20–25 (In Russ.) Available at: https://elibrary.ru/syqkct.

28. Kurko TA, Saastamoinen LK, Tähkäpää S, Tuulio-Henriksson A, Taiminen T, Tiihonen J et al. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037–1047. https://doi.org/10.1016/j.eurpsy.2015.09.003.

29. Neznamov GG, Metlina MV, Bogdanova NI, Kuznetsov NA, Syunyakov SA. The subjective evaluation by patients of the effects of anxiolytics: the dependence on the syndromal structure of anxiety disorders. Psikhiatriya i Psikhofarmakoterapiya. 2017;19(3):10–18. (In Russ.) Available at: https://elibrary.ru/zmqsml.

30. Vasilyeva AV. Posttraumatic stress disorder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2024;124(5):58–68. (In Russ.) https://doi.org/10.17116/jnevro202412405158.

31. Nekhoroshkova AN, Bolshevidtseva IL. Neurobiological prerequisites for the formation of anxiety states. Vestnik of Northern (Arctic) Federal University. 2016;(3):24–36. (In Russ.) Available at: https://vestnikgum.ru/archive/?ELEMENT_ID=258831.

32. Grigorova OV, Akhapkin RV, Alexandrovsky Yu A. Modern concepts of pathogenetic therapy of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(10):111–120. (In Russ.) https://doi.org/10.17116/jnevro2019119101111.

33. Petrova NN. Buspiron in the treatment of addictive disorders: past, present, future. RMJ. Medical Review. 2023;7(10):644–649. (In Russ.) https://doi.org/10.32364/2587-6821-2023-7-10-5.

34. Bykov YuV, Becker RA. Buspiron in psychiatric practice: is it only an anxiolytic? Psikhiatriya i Psikhofarmakoterapiya. 2017;19(5):32–52. (In Russ.) Available at: https://www.elibrary.ru/zvytvj.

35. Tsybulya OV, Poplavskaya AV, Kozhanov Yu V. The effectiveness of buspiron (spitomine) in the treatment of comorbid mental disorders. Lekarstvennyi Vestnik. 2017;11(1):38–43. (In Russ.) Available at: https://www.elibrary.ru/yrxbzj.

36. Veltischev DY. Diagnostics and treatment of generalized anxiety disorder (Literature review). Current Therapy of Mental Disorders. 2018;(3):26–37. (In Russ.) https://doi.org/10.21265/PSYPH.2018.46.16769.

37. Vasilyeva A, Karavaeva T, Poltorak S. Combined therapy for panic disorders in cardiology practice. Vrach. 2017;28(8):18–21. (In Russ.) Available at: https://www.elibrary.ru/zevatf.

38. Volel BA, Petelin DS, Akhapkin RV, Malyutina AA. Cognitive impairment in anxiety disorders. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):78–82. (In Russ.) https://doi.org/10.14412/2074-2711-2018-1-78-82.

39. Martynikhin IA, Neznanov NG. Special Aspects of Generalized Anxiety Disorder Diagnosing Among Russians Psychiatrists: the Results of a Vignette Study. Current Therapy of Mental Disorders. 2018;(4):51–59. (In Russ.) Available at: https://www.elibrary.ru/vpkbpm.

40. Bogolepova AN. Cognitive impairment in post-traumatic stress disorder. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2024;124(5):69–74. (In Russ.) https://doi.org/10.17116/jnevro202412405169.

41. Van Praag DLG, Cnossen MC, Polinder S, Wilson L, Maas AIR. Post-Traumatic Stress Disorder after Civilian Traumatic Brain Injury: A Systematic Review and Meta-Analysis of Prevalence Rates. J Neurotrauma. 2019;36(23):3220–3232. https://doi.org/10.1089/neu.2018.5759.

42. Diminich ED, Clouston SAP, Kranidis A, Kritikos M, Kotov R, Kuan P et al. Chronic Posttraumatic Stress Disorder and Comorbid Cognitive and Physical Impairments in World Trade Center Responders. J Trauma Stress. 2021;34(3):616–627. https://doi.org/10.1002/jts.22631.

43. Караваева ТА, Васильева АВ, Идрисов КА, Ковлен ДВ, Незнанов НГ, Пономаренко ГН и др. Посттравматическое стрессовое расстройство: клинические рекомендации. М.; 2023. Режим доступа: https://cr.minzdrav.gov.ru/recomend/753_1.

44. Kostyukova EG, Ladyzhensky MYa. Differentiated pharmacotherapy of generalized anxiety disorder. Current Therapy of Mental Disorders. 2018;(1):45–52. (In Russ.) https://doi.org/10.21265/PSYPH.2018.44.11591.

45. Karavaeva TA, Vasilyeva AV, Poltorak SV, Kolesova Yu P. Principles and algorithms of neurotic level anxiety disorders (anxiety-phobic, panic and generalized anxiety disorder psychopharmacological treatment. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2016;(1):3–9. (In Russ.) Available at: https://www.elibrary.ru/wfetfj.